The Latest Notice of National Acquisition of Consumables, Launched on August 1.
2022-08-08
National centralized procurement of spine is starting to report the requirement of volume
Recently, the state organization，Joint Procurement Office of High-value Medical Consumables issued the Notice on Filling in the Procurement Needs of Medical Institutions for Spinal Consumables(hereinafter referred to as the Notice), requiring the medical institutions in the areas under the jurisdiction of the alliance to fill in the demand data from 12:00 on August 1 to 17:00 on August 14, 2022.
The products purchased in this centralized volume are orthopedic spine medical consumables, including 14 product system categories: cervical anterior screw plate fixation and fusion system, cervical posterior screw rod fixation system, thoracolumbar anterior screw rod fixation and fusion system, thoracolumbar anterior screw plate fixation and fusion system, thoracolumbar posterior open screw rod fixation and fusion system, thoracolumbar posterior minimally invasive screw rod fixation and fusion system, cervical posterior spinal canal expansion screw plate fixation system Vertebroplasty system, kyphoplasty system, percutaneous endoscopic lumbar nucleus pulposus enucleation system, intervertebral disc system, cervical fusion cage system alone, thoracolumbar fusion cage system alone, bone cement for spine.
The Public medical institutions in the union region that use spinal medical consumables in 2021 shall participate. The Joint Procurement Office of High-value Medical Consumables issued the “Announcement on Centralized Procurement of Orthopedic Spine Consumables Organized by the State (No. 1) (referred to as Announcement No. 1).
According to the content of Announcement No. 1, the grouping and rules are not much different from the announcement of national procurement of artificial joints, and too much information has not been disclosed.
Some experts believe that, based on the experience of the first round of national procurement, artificial joint national procurement pays more attention to market share and product attributes in grouping, which is more suitable for clinical use, and the price reduction in the second round is relatively mild. In addition, combined with the accumulated experience and opinions of the second round of national procurement, enterprises should give corresponding feedback in the next forum. “For example, adjusting the price of accompanying services so that companies can have the ability to absorb this cost.”
Will the winning rate increase?
It is clearly written in the Announcement No.1 that “under the premise of ensuring fair competition, maintaining the intensity of competition and eliminating the false high price space, more enterprises will be promoted to win and the expected stability will be enhanced by adopting appropriate methods”.
Does “Let more companies be elected” mean that the national procurement will be mild this time?
Relevant experts believe that the winning rate is not very important. Although the winning rate of the second national procurement is significantly higher than that of the first, it also depends on the amount of procurement allocated.
“Those companies that were assigned to 2, 5 or 100 in joint national procurement were actually equivalent to being eliminated from the game.
Because the distribution of procurement volume itself varied greatly, some leading enterprises in joint national procurement may be allocated more than 20,000. According to its final bid price, a single product was 200 million yuan, but for some small enterprises, such a high distribution volume was simply impossible. “
Innovation will be the new normal
In fact, the changes after centralized procurement are very obvious. Taking coronary stents as an example, the national procurement force many enterprises to enter into the adjacent subdivisions, such as heart valves and electrophysiology, and even some other subdivisions, such as medical robots, to adjust and extend the enterprise strategy of the whole company.
“Although this change has caused great pressure on enterprises, it is an opportunity for domestic leading enterprises.” Some experts believe that.
First, it promotes the substitution of domestic products for imports, which is conducive to the rapid expansion of domestic head enterprises; The second is to force the enterprises covered by centralized purchase to extend more non centralized purchase products and to extend to the subdivided fields; Third, in fact, it has promoted the development and use of some more advanced products or innovative products. For example, some head enterprises of coronary stents have started to make biodegradable stents, and the usage has increased by at least 50% ~ 60%.
At the regular policy briefing of the State Council this year, it was pointed out that since the centralized procurement, the R & D expenses of some enterprises, especially the leading enterprises, have gradually increased, and the R & D expenses of some leading enterprises have increased from 6% and 10% to 20%. On the one hand, the leading enterprises can do imitation; on the other hand, the leading enterprises should turn to innovation.
BradyKnows localization team has extensive experiences in facility establishment, audit, supplier evaluation, manufacturing, registration, and marketing in China. Pls feel free to let us know any questions on China entry via info@bradyknowsmedical.com
